Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Avidity Biosciences stock | $21.94

Learn how to easily invest in Avidity Biosciences stock.

Avidity Biosciences Inc is a biotechnology business based in the US. Avidity Biosciences shares (RNA) are listed on the NASDAQ and all prices are listed in US Dollars. Avidity Biosciences employs 71 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Avidity Biosciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RNA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Avidity Biosciences stock price (NASDAQ: RNA)

Use our graph to track the performance of RNA stocks over time.

Avidity Biosciences shares at a glance

Information last updated 2021-10-23.
Latest market close$21.94
52-week range$17.58 - $36.02
50-day moving average $22.69
200-day moving average $22.44
Wall St. target price$46.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.07

Buy Avidity Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Avidity Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avidity Biosciences price performance over time

Historical closes compared with the close of $21.94 from 2021-10-25

1 week (2021-10-19) 2.57%
1 month (2021-09-24) -6.36%
3 months (2021-07-26) 9.43%
6 months (2021-04-26) -12.66%
1 year (2020-10-26) -19.69%
2 years (2019-10-22) N/A
3 years (2018-10-22) N/A
5 years (2016-10-22) N/A

Avidity Biosciences financials

Revenue TTM $9.2 million
Gross profit TTM $-30,815,000
Return on assets TTM -15.09%
Return on equity TTM -26.2%
Profit margin 0%
Book value $7.02
Market capitalisation $1 billion

TTM: trailing 12 months

Shorting Avidity Biosciences shares

There are currently 5.6 million Avidity Biosciences shares held short by investors – that's known as Avidity Biosciences's "short interest". This figure is 3.8% up from 5.4 million last month.

There are a few different ways that this level of interest in shorting Avidity Biosciences shares can be evaluated.

Avidity Biosciences's "short interest ratio" (SIR)

Avidity Biosciences's "short interest ratio" (SIR) is the quantity of Avidity Biosciences shares currently shorted divided by the average quantity of Avidity Biosciences shares traded daily (recently around 558970.66402379). Avidity Biosciences's SIR currently stands at 10.09. In other words for every 100,000 Avidity Biosciences shares traded daily on the market, roughly 10090 shares are currently held short.

However Avidity Biosciences's short interest can also be evaluated against the total number of Avidity Biosciences shares, or, against the total number of tradable Avidity Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avidity Biosciences's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Avidity Biosciences shares in existence, roughly 120 shares are currently held short) or 0.1357% of the tradable shares (for every 100,000 tradable Avidity Biosciences shares, roughly 136 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Avidity Biosciences.

Find out more about how you can short Avidity Biosciences stock.

Avidity Biosciences share dividends

We're not expecting Avidity Biosciences to pay a dividend over the next 12 months.

Avidity Biosciences overview

Avidity Biosciences, Inc. , a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.

Frequently asked questions

What percentage of Avidity Biosciences is owned by insiders or institutions?
Currently 9.052% of Avidity Biosciences shares are held by insiders and 85.591% by institutions.
How many people work for Avidity Biosciences?
Latest data suggests 71 work at Avidity Biosciences.
When does the fiscal year end for Avidity Biosciences?
Avidity Biosciences's fiscal year ends in December.
Where is Avidity Biosciences based?
Avidity Biosciences's address is: 10975 North Torrey Pines Road, La Jolla, CA, United States, 92037
What is Avidity Biosciences's ISIN number?
Avidity Biosciences's international securities identification number is: US05370A1088
What is Avidity Biosciences's CUSIP number?
Avidity Biosciences's Committee on Uniform Securities Identification Procedures number is: N71546100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site